349536-39-6 Usage
Description
6'-DesMethyl-6'-carboxy Etoricoxib is a derivative of Etoricoxib (E934100), a selective cyclo-oxygenase-2 (COX-2) inhibitor. It is characterized by the absence of a methyl group at the 6' position and the presence of a carboxy group at the same position. This modification potentially alters the pharmacological properties and applications of the original Etoricoxib.
Uses
Used in Pharmaceutical Industry:
6'-DesMethyl-6'-carboxy Etoricoxib is used as a therapeutic agent for the treatment of various inflammatory conditions, particularly osteoarthritis and rheumatoid arthritis. As a COX-2 inhibitor, it helps improve the signs and symptoms associated with these conditions by reducing inflammation and pain.
Used in Research and Development:
6'-DesMethyl-6'-carboxy Etoricoxib may also be utilized in research and development for the discovery of new drugs with improved efficacy, safety, and pharmacokinetic profiles. Its unique structural features could provide valuable insights into the design of novel COX-2 inhibitors and other related compounds.
Used in Drug Delivery Systems:
Similar to Gallotannin, 6'-DesMethyl-6'-carboxy Etoricoxib could be incorporated into drug delivery systems to enhance its bioavailability, targeting, and therapeutic outcomes. This may involve the use of nanoparticles, liposomes, or other advanced drug delivery technologies to improve the drug's performance in treating inflammatory conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 349536-39-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,4,9,5,3 and 6 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 349536-39:
(8*3)+(7*4)+(6*9)+(5*5)+(4*3)+(3*6)+(2*3)+(1*9)=176
176 % 10 = 6
So 349536-39-6 is a valid CAS Registry Number.
349536-39-6Relevant articles and documents
In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663)
Chauret, Nathalie,Yergey, James A,Brideau, Christine,Friesen, Richard W,Mancini, Joseph,Riendeau, Denis,Silva, Jose,Styhler, Angela,Trimble, Laird A,Nicoll-Griffith, Deborah A
, p. 1059 - 1062 (2007/10/03)
Characterization of the metabolites of the COX-2 inhibitor etoricoxib (MK-0663 and L-791, 456) produced in vitro indicate formation of an N-oxide pyridine and hydroxymethyl pyridine that can further be glucuronidated or oxidized to an acid. Significant turnover is observed in human hepatocytes. Several CYPs are involved in the oxidative biotranformations and, from in vitro studies, etoricoxib is not a potent CYP3A4 inducer or inhibitor. Based on an in vitro whole blood assay, none of the metabolites of etoricoxib inhibits COX-1 or contributes significantly to the inhibition of COX-2.
